CD59 and colonic neoplasm: Our observation that CD59 acts as an immune-suppressive Siglec-9 ligand agrees with previous observations that protein expression of CD59 in human PCa (49) and other solid tumors, including colon cancer (50), breast cancer (51), NLCLC cancer (52), and esophageal squamous cell carcinoma (53) is associated with adverse outcomes.